Navigation Links
Report by U.S. Government Research Scientists Confirms Bio Terror Threat Detection Capabilities of PathSensor’s CANARY Technology
Date:2/23/2017

Baltimore biotech firm, PathSensors, Inc., announced today that in a published evaluation of multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest Laboratory (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the best level of detection (LOD) for two bio terror threats, Bacillus anthracis (anthrax) and Ricin.

The report, "Evaluation of Immunoassays and General Biological Indicator Tests for Field Screening of Bacilus anthracis and Ricin," compared fourteen immunoassays from ten different technology providers, including PathSensor’s CANARY biosensor immunoassay and PathSensor’s Zephyr assay sample reader.

A measure of the effectiveness of bio terror and bio threat detection technologies is the technology’s tested “limit of detection,” which indicates the level of sensitivity of the technology and its ability to avoid false positives (false alarms). A lower limit of detection indicates a better level of threat detection sensitivity and lower false alarm rate and is more desirable for bio threat detection applications. In the case of PathSensors’ CANARY® Zephyr technology, the PNNL report found that for detection of bacillus anthracis:

“….the CANARY Zephyr achieved an estimated limit of detection of 10^3 spores/mL, which was 4 orders of magnitude lower than any other immunoassay tested.” [PNNL report, page 87]

For detection of Ricin toxin, the PNNL report found that:

“…The CANARY Zephyr achieved the lowest limit of detection (3ng/mL).” [PNNL report, page 87]

“This new report from PNNL scientists is only the latest in what has been a series of independent validations of PathSensors’ CANARY pathogen detection technology,” commented Ted Olsen, CEO, PathSensors, Inc. “Anthrax and Ricin are just two of the many pathogens CANARY can detect; now users of CANARY can know that they are using one of the most highly sensitive and cost effective bio threat solutions available.”

PathSensors’ CANARY® (Cellular Analysis and Notification of Antigen Risks and Yields) technology is a biosensor technology that delivers rapid detection
of pathogens – including toxins, viruses, and bacteria – at high levels of sensitivity and specificity. First developed at the MIT-Lincoln Laboratory, CANARY® incorporates pathogen-specific antibodies expressed on the biosensor surface which, in the presence of a pathogen, trigger an intracellular calcium release that in turn activates bioluminescent proteins whose light output can be measured and analyzed. In independent tests by U.S. government labs, PathSensors’ CANARY® technology was shown to be superior to alternative technologies in terms of sensitivity and speed of detection. PathSensors has a continually growing library of biosensors for threats such as HLB, Phytophthora, and Ebola.

About PathSensors, Inc.
PathSensors is a leading biotechnology solutions and environmental testing company. PathSensors provides high speed, highly sensitive pathogen and threat detection solutions for the defense, homeland security, public health, medical countermeasures, mail room screening, first responder, food processing and agricultural sectors. For more information, visit http://www.pathsensors.com.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14087069.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PharmAthene Reports Year-End 2012 Financial And Operational Results
2. Global Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) - 2013 Market Report
3. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
4. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
5. Animal Biotechnology 2013 Market Report
6. Global Biochips and Microarrays 2013 Market Report
7. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
8. Ingenuity Systems and GeneInsight to Deliver an Interpretation and Reporting Workflow Solution to Clinical Laboratories
9. Global Bio-implants Market 2012-2016 New Research Report Now Available at MarketResearchReports.biz
10. RNAi - Technologies, Markets and Companies - 2013 Report
11. Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... VEGAS (PRWEB) , ... October 10, 2019 , ... R3 ... courses. The next course is October 18-19th, 2019 in Las Vegas with spots still ... exosomes. He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. ...
(Date:10/8/2019)... (PRWEB) , ... October 07, 2019 , ... ... of low level laser therapy technology (“3LT®”), today announces that the U.S. Food ... its EVRL low level laser for the temporary relief of chronic neck and ...
(Date:10/3/2019)... ... 2019 , ... Cheyenne is a beautiful and strong Quarter Horse and a ... Rebel’s Run , which offers riding lessons and trail riding in Afton, Virginia. ... Mimi describes her as her “go to horse.” Thus, you can imagine ...
(Date:10/3/2019)... ... October 02, 2019 , ... eKare’s inSight® digital 3D imaging and ... run by the East Midlands Academic Health Science Network (EMAHSN), the innovation arm of ... NHS by providing support to develop and deploy solutions to the most pressing challenges ...
Breaking Biology Technology:
(Date:9/30/2019)... ... September 30, 2019 , ... RoosterBio ... stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval ... formats (patent number AU 2015259373). This new patent adds intellectual property (IP) ...
(Date:9/25/2019)... , ... September 25, 2019 , ... ... pleased to announce it ranked No. 3094 on Inc. Magazine’s annual Inc. 5000 ... reported three-year revenue growth of 120 percent. Based on this growth, the Houston-based ...
(Date:9/24/2019)... and CAMBRIDGE, Mass. (PRWEB) , ... September 23, ... ... Budapest with US offices in Cambridge, MA, announce today that Holotype HLA and ... at the annual meeting of the American Society for Histocompatibility and Immunogenetics ...
Breaking Biology News(10 mins):